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Background: Sentinel lymph node biopsy (SLNB) is rapidly becoming the standard
of care in the treatment of women with early stage breast cancer. Male breast cancer
although relatively rare, has typically been treated with mastectomy and axillary
lymph node dissection (ALND). Men who develop breast carcinoma have the same
risk as their female counterparts of developing the morbidities associated with axillary
dissection. SLNB has been championed as a procedure aimed at preventing those
morbidities. We recently have evaluated the role of SLNB in the treatment of men with
early stage breast cancer.
Methods: Among the 18 men treated at the University of MichiganMedical Center for
breast cancer from May 1998 to November 2002, 6 were treated with SLNB.
Results: The mean tumor size was 1.6 cm. The mean patient age was 59.8 years. All of
the patients had one or more sentinel lymph nodes identified. Two of the six did not
have confirmatory axillary dissection. Three of the six had positive sentinel lymph
nodes (50%). Only one of the three patients with a positive sentinel node had more
nodes positive. One of the six patients had a positive node on frozen section and
underwent immediate complete axillary dissection. This patient had no additional
positive nodes. No patients in our series had immunohistochemical studies of the
lymph nodes.
Conclusions: Men with early stage breast carcinoma may be offered the management
option of SLNB since in the hands of experienced surgeons it has a success rate
apparently equal to that in their female counterparts.
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INTRODUCTION
Male breast cancer is a rare entity, accounting for
approximately 1% of all cases of breast carcinoma [1].
For this reason, the data available to evaluate treatment
outcomes has not been abundant and much of what we
know and what we do in breast cancer is extracted from
knowledge of breast carcinoma in women. In an attempt
to avoid the morbidity associated with axillary dissection,
sentinel lymph node biopsy (SLNB) has become widely
implemented in the treatment of female breast cancer [2].
Men are at no less risk for the development of the
morbidities associated with axillary dissection. The po-
tential impact for the male, though no more or less than
the female, may be somewhat different. For males, since
they frequently have vocations in which the physical
activity may be more pronounced the impact may be
more devastating. With this in mind it is therefore, rea-
sonable to apply the technology of SLNB to males with
breast carcinoma.
MATERIALS AND METHODS
Between May 1998 and November 2002, 18 men were
seen with breast cancer at the University of Michigan
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Cancer Center. Six men underwent SLNB. Five of the six
patients had radioisotope tracer injected followed by
lymphoscintigraphy and all six had blue dye injected. The
five patients who had the radioisotope injected received a
peritumoral injection of 0.3 m Ci of Tc-99 m unfiltered
sulfur colloid (Cis US, Bedford, MA) in 4 cc of normal
saline. This was given a minimum of 2 hr prior to the
surgery. In the operating room 4 cc of isosulfan blue dye
(Lymphazurin, Zenith Parenterals, Rosemont, IL) were
given as a peritumoral injection in four patients and 3 cc
peritumoral with 1 cc intradermal in two patients. The
one patient who received lymphazurin blue but no
radionucleide was undiagnosed prior to surgery and
underwent a biopsy of the mass with frozen section. Fol-
lowing intraoperative confirmation of the carcinoma the
patient was injected with lymphazurin blue and the
sentinel node was identified.
The SLNB was then performed in all six patients. The
gamma probe (Navigator GPS, U.S. Surgical, Norwalk,
CT) and blue dye were used to guide us toward the
sentinel nodes via the lymphatics. When the background
counts in the axilla decreased tenfold and the dye was no
longer visible, we terminated our pursuit of the sentinel
lymph nodes. One patient had a frozen section of what
appeared to be an obvious positive lymph node. After
confirmation, he underwent an immediate axillary
dissection. All patients had at least one sentinel lymph
node identified. No patients underwent immunohisto-
chemical analysis for the presence of cytokeratin.
The sentinel lymph nodes were processed in the
following manner: briefly, each sentinel node was
measured and entirely cut along its longitudinal axis into
sections of 1.5–2 mm thickness. The sections were
submitted in formalin for paraffin section histology. Each
paraffin block was sectioned at three levels.
RESULTS
All patients were clinically node-negative preopera-
tively. The average ages of the patients were 59.8 years
(range 51–67). Five patients (83%) were Caucasian and
one was African American (17%). Five of the six patients
had a palpable mass, one of who had a concomitant
yellow nipple discharge. One patient presented with a
bloody nipple discharge and no palpable mass. Two of the
six presented with micro-calcifications. Pathological data
on the tumors of these patients can be found in Table I.
Four patients (66.7%) had infiltrating ductal carci-
noma, one patient (16.6%) had extensive DCIS, and one
patient (16.6%) had intracystic papillary carcinoma with
evidence of microinvasion. The estrogen receptor status
was only determined in the four patients with invasive
ductal carcinoma and they were all positive. The sentinel
lymph node was successfully identified in all six patients.
The mean number of sentinel lymph nodes removed was
2.2. Three of the six patients (50%) had a positive sentinel
lymph node and only one of these had additional lymph
nodes positive.
Four of the six patients underwent a completion
axillary lymph node dissection (ALND). Only one of
the four had additional positive lymph nodes [6]. One of
the patients underwent frozen section analysis, which was
positive. This was followed by a completion axillary
dissection in which all nodes were negative. The results
of the sentinel node procedure are highlighted in Table II.
To date, there have been very few reports involving the
use of SLNB in males. In order to review this topic, we
combined our patients with those of two previous reports
[10,15]. This allowed us to create a pooled database of 23
patients as shown in Tables III and IV.
DISCUSSION
Male breast carcinoma accounts for approximately
1% of all breast cancers. The histological status of the
axillary nodes remains the single best prognostic factor in
TABLE I. Pathological Data on Tumors in Male Breast




Invasive ductal carcinoma 4 (66.7)




Mean tumor size (cm) 1.6 (range 0.7–2.8)
Tumor location
Central 4 (66.7)
Lower outer 1 (16.7)



















DCIS, ductal carcinoma in situ; ER, estrogen receptor.
*ER, status not determined for two patients; one with extensive DCIS
and one with DCIS and microvasion.
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both male and female patients with breast cancer [3,4].
Traditionally, ALNDwith histological examination of the
axillary lymph nodes is essential in the planning of
adjuvant chemotherapy in patients with breast cancer.
ALND may be associated with scarring, numbness, loss
of range of motion and lymphedema [5].
The standard treatments for breast carcinoma in men
have been closely aligned to the treatments in women.
Ongoing research in the management of early stage
breast carcinoma in women is aimed at improving sur-
vival and decreasing morbidity. Recently the concept of a
minimally-invasive strategy to stage the nodal basin has
emerged, altering the traditional staging algorithm based
on a level I/II ALND. Studies have shown that sentinel
node biopsy (SLNB) can reliably predict the status of the
axilla, so that when the sentinel node is clear, the entire
axilla can be assumed to be negative and axillary
dissection can be avoided [6,7]. The technique has been
validated by many studies documenting consistently high
success rates and low false negative rates [8,9]. To date,
there has been no series documenting significant rates of
axillary recurrence or lymphedema in women who have
undergone SLNB alone.
Men are at risk for the same complications as women
with respect to axillary dissection. The potential clinical
implications of sentinel node biopsy have different yet
equally important concerns related to axillary morbidity.
Department of Labor Statistics indicate that men com-
prise the vast majority of the manual labor force in the
United States, accounting for roughly 60% of all workers
in the manufacturing sector and close to 90% of all
workers in industries like mining and construction [10].
This being the case, a significant positive impact on
postoperative morbidity and a patient’s return to work
capability should be realized. We can anticipate that
SLNB will reduce direct costs as result of shorter operat-
ing time and hospital stay as well as indirect costs
because of the reduced postoperative activity that some-
times prevents full use of the arm and therefore, de-
creased productivity in the workplace.
Although the population-based Surveillance Epide-
miology End Result (SEER) Database concluded that
males present with significantly (P< 0.001) larger pri-
mary tumors and more positive axillary nodes than did
TABLE II. Sentinel Lymph Node Data (n¼ 6)
Sentinel node detection data (n¼ 6) Number (%)
Mean no. of sentinel nodes/patient (range) 2.3 (1–4)
Sentinel node successfully identified 6 (100)
Failure 0 (0)




Not done 1 (16.7)
Lymph node blue only 1 (16.7)
Lymph node hot only 0 (0)
Lymph node hot and blue 5 (83.3)
*All lymph node positive by HþE.
TABLE III. Combination of Data From two Previous Studies
[10,15] and the University of Michigan on Tumors in Male
Breast Carcinoma Patients who Underwent Sentinel Lymph
Node Biopsy (n¼ 23)
Characteristic Number (%)
Tumor type
Invasive ductal carcinoma 19 (82.6)




Mean tumor size (cm.) 1.4 (range 0.1–3)
Tumor location
Central 14 (60.9)
Lower outer 1 (4.4)
Upper inner 2 (8.7)
















DCIS, ductal carcinoma in situ; ER, estrogen receptor.
*ER, status not determined for four patients; two with extensive DCIS
and microinvasion.
TABLE IV. Sentinel Lymph Node Data From two Previous Studies
[10,15] and the University of Michigan (n¼ 23)
Sentinel node detection data (n¼ 23) No. (%)
Mean no. of sentinel nodes/patient (range) 2.67 (1–4)
Sentinel node successfully identified 22 (95.7)
Failure 1 (4.4)
Patients with positive sentinel nodes 9 (39.1)
Positive by frozen section 3 (13.0)
Positive by HþE only 6 (26.1)




Not done 1 (4.4)
Lymph node blue only 2 (8.7)
Lymph node hot only 0
Lymph node hot and blue 20 (87.0)
IHC, immunohistochemistry.
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women [16], there are recent reports that demonstrate the
remarkable parallels in the histopathology and prognosis
of male and female breast cancer [14]. For example,
molecular biological studies demonstrate a similar
incidence of p53 mutations in the tumors of both men
and women [11]. The 10-year survival for men with stage
I (T1NOMO) disease is the same as in women (89%)
[12]. SLNB in female patients with T2 breast tumors
appears to have similar success rates and false negative
rates when comparing it to those female breast cancer
patients with T1 tumors [13]. The role of sentinel
lymphadenectomy in males with T2 tumors may be
harder to define because of the low numbers but we may
safely assume that its success will mirror the excellent
results seen in females. From the pooled data presented in
this report of 19 patients with T1 tumors, 8 had positive
sentinel lymph nodes (42%) detected by either HþE or
IHC methods. This incidence of positive sentinel nodes is
similar to many of the larger series in women.
CONCLUSION
Sentinel node biopsy in male patients with early stage
breast cancers is comparable to its use in women. It seems
to be a simple and reliable method for staging the axilla
accurately, avoiding the complications of axillary dis-
section with the secondary benefit of cost reduction.
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